FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It
Quick Read FBT's equal-weight design beat IBB by 35 percentage points over five years, returning 47% versus IBB's 13% despite carrying a higher expense ratio. IBB puts nearly 30% into four mega-caps (Vertex, Amgen, Gilead, and Regeneron), making it behave more like a defensive he


